StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$32.43+1.23 (+3.94%)

Close on Nov 19, 2026Market cap $1.80BP/E –Yield –

Maze Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Maze Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$106.84M. For fiscal 2025 it was -$112.73M, down 250.7% from the year before.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$112.73M-250.7%
FY2024Dec 31, 2024$74.81M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.16M–
Q1 FY2026Mar 31, 2026-$39.21M–
Q4 FY2025Dec 31, 2025-$27.76M–
Q3 FY2025Sep 30, 2025-$24.71M–
Q2 FY2025Jun 30, 2025-$30.45M-121.0%
Q1 FY2025Mar 31, 2025-$29.82M–
Q4 FY2024Dec 31, 2024-$23.06M–
Q3 FY2024Sep 30, 2024-$23.31M–
Q2 FY2024Jun 30, 2024$144.89M–
Q1 FY2024Mar 31, 2024-$23.72M–

More Maze Therapeutics figures

See a number that looks wrong?